SSY Group’s H1 2025 revenue and profit fall amid market challenges

SSY Group Limited reported revenue of HK$2.15 bn for the six months ended June 30, 2025, a 35.7% decrease from HK$3.34 bn in the same period last year. Net profit attributable to equity shareholders also saw a substantial fall of 58.7% to HK$283.5m from HK$685.7m. This downturn was primarily attributed to insufficient growth in domestic and international demand, continuous product price declines, and deepening adjustments in industry policies, particularly affecting intravenous infusion solutions and ampoule injections.

Despite the challenging environment, the Group is actively expanding market access for new and advantageous products, participating in national and local centralised procurement initiatives, and strengthening R&D. The board has declared an interim dividend of HKD 0.05 per share, payable on September 26, 2025, to shareholders registered by September 12, 2025, a decrease from HKD 0.08 per share in the prior year.

Furthermore, SSY Group repurchased 22.7m ordinary shares for approximately HK$66.2m during the period, with 6.1m shares cancelled and 16.6m held as treasury shares. The company maintains its commitment to sustainable development and is accelerating infrastructure projects to enhance industrialization efficiency.